AccessMedicine | Print: Chapter 260.

Chronic Obstructive Pulmonary Disease

Page 1 of 19

Note: Large images and tables on this page may necessitate printing in landscape mode.
Copyright The McGraw-Hill Companies. All rights reserved.
Harrison's Online > Chapter 260. Chronic Obstructive Pulmonary Disease >

CHRONIC OBSTRUCTIVE PULMONARY DISEASE:

INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is defined as a disease state characterized by airflow
limitation that is not fully reversible (http://www.goldcopd.com/). COPD includes emphysema, an
anatomically defined condition characterized by destruction and enlargement of the lung alveoli;
chronic bronchitis, a clinically defined condition with chronic cough and phlegm; and small airways
disease, a condition in which small bronchioles are narrowed. COPD is present only if chronic airflow
obstruction occurs; chronic bronchitis without chronic airflow obstruction is not included within
COPD.
COPD is the fourth leading cause of death and affects >10 million persons in the United States.
COPD is also a disease of increasing public health importance around the world. Estimates suggest
that COPD will rise from the sixth to the third most common cause of death worldwide by 2020.

RISK FACTORS
Cigarette Smoking
By 1964, the Advisory Committee to the Surgeon General of the United States had concluded that
cigarette smoking was a major risk factor for mortality from chronic bronchitis and emphysema.
Subsequent longitudinal studies have shown accelerated decline in the volume of air exhaled within
the first second of the forced expiratory maneuver (FEV1) in a dose-response relationship to the
intensity of cigarette smoking, which is typically expressed as pack-years (average number of packs
of cigarettes smoked per day multiplied by the total number of years of smoking). This doseresponse relationship between reduced pulmonary function and cigarette smoking intensity accounts
for the higher prevalence rates for COPD with increasing age. The historically higher rate of smoking
among males is the likely explanation for the higher prevalence of COPD among males; however,
the prevalence of COPD among females is increasing as the gender gap in smoking rates has
diminished in the past 50 years.
Although the causal relationship between cigarette smoking and the development of COPD has been
absolutely proved, there is considerable variability in the response to smoking. Although pack-years
of cigarette smoking is the most highly significant predictor of FEV1 (Fig. 260-1), only 15% of the
variability in FEV1 is explained by pack-years. This finding suggests that additional environmental
and/or genetic factors contribute to the impact of smoking on the development of airflow
obstruction.

Figure 260-1

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 2 of 19

Distributions of forced expiratory volume in 1 s (FEV1) values in a general population sample,

stratified by pack-years of smoking. Means, medians, and 1 standard deviation of percent predicted
FEV1 are shown for each smoking group. Although a dose-response relationship between smoking intensity
and FEV1 was found, marked variability in pulmonary function was observed among subjects with similar
smoking histories. (From B Burrows et al: Am Rev Respir Dis 115:95, 1977; with permission.)

Although cigar and pipe smoking may also be associated with the development of COPD, the
evidence supporting such associations is less compelling, likely related to the lower dose of inhaled
tobacco by-products during cigar and pipe smoking.

Airway Responsiveness and COPD

A tendency for increased bronchoconstriction in response to a variety of exogenous stimuli,
including methacholine and histamine, is one of the defining features of asthma (Chap. 254).
However, many patients with COPD also share this feature of airway hyperresponsiveness. The
considerable overlap between persons with asthma and those with COPD in airway responsiveness,
airflow obstruction, and pulmonary symptoms led to the formulation of the Dutch hypothesis. This
suggests that asthma, chronic bronchitis, and emphysema are variations of the same basic disease,
which is modulated by environmental and genetic factors to produce these pathologically distinct
entities. The alternative British hypothesis contends that asthma and COPD are fundamentally
different diseases: Asthma is viewed as largely an allergic phenomenon, while COPD results from

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 3 of 19

smoking-related inflammation and damage. Determination of the validity of the Dutch hypothesis
vs. the British hypothesis awaits identification of the genetic predisposing factors for asthma and/or
COPD, as well as the interactions between these postulated genetic factors and environmental risk
factors. Of note, several genes related to the proteinase-antiproteinase hypothesis have been
implicated as genetic determinants for both COPD and asthma, including ADAM33 and macrophage
elastase (MMP12) as described below.
Longitudinal studies that compared airway responsiveness at the beginning of the study to
subsequent decline in pulmonary function have demonstrated that increased airway responsiveness
is clearly a significant predictor of subsequent decline in pulmonary function. Thus, airway
hyperresponsiveness is a risk factor for COPD.

Respiratory Infections
The impact of adult respiratory infections on decline in pulmonary function is controversial, but
significant long-term reductions in pulmonary function are not typically seen following an episode of
bronchitis or pneumonia. The impact of the effects of childhood respiratory illnesses on the
subsequent development of COPD has been difficult to assess due to a lack of adequate longitudinal
data. Thus, although respiratory infections are important causes of exacerbations of COPD, the
association of both adult and childhood respiratory infections to the development and progression of
COPD remains to be proven.

Occupational Exposures
Increased respiratory symptoms and airflow obstruction have been suggested to result from general
exposure to dust and fumes at work. Several specific occupational exposures, including coal mining,
gold mining, and cotton textile dust, have been suggested as risk factors for chronic airflow
obstruction. Although nonsmokers in these occupations developed some reductions in FEV1, the
importance of dust exposure as a risk factor for COPD, independent of cigarette smoking, is not
certain for most of these exposures. However, a recent study found that coal mine dust exposure
was a significant risk factor for emphysema in both smokers and nonsmokers. In most cases, the
magnitude of these occupational exposures on COPD risk is likely substantially less important than
the effect of cigarette smoking.

Ambient Air Pollution

Some investigators have reported increased respiratory symptoms in those living in urban
compared to rural areas, which may relate to increased pollution in the urban settings. However,
the relationship of air pollution to chronic airflow obstruction remains unproved. Prolonged exposure
to smoke produced by biomass combustiona common mode of cooking in some countriesalso
appears to be a significant risk factor for COPD among women in those countries. However, in most
populations, ambient air pollution is a much less important risk factor for COPD than cigarette
smoking.

Passive, or Second-Hand, Smoking Exposure

Exposure of children to maternal smoking results in significantly reduced lung growth. In utero
tobacco smoke exposure also contributes to significant reductions in postnatal pulmonary function.
Although passive smoke exposure has been associated with reductions in pulmonary function, the
importance of this risk factor in the development of the severe pulmonary function reductions in
COPD remains uncertain.

Genetic Considerations
Although cigarette smoking is the major environmental risk factor for the development of COPD, the
development of airflow obstruction in smokers is highly variable. Severe 1 antitrypsin ( 1AT)

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 4 of 19

deficiency is a proven genetic risk factor for COPD; there is increasing evidence that other genetic
determinants also exist.

1 ANTITRYPSIN DEFICIENCY
Many variants of the protease inhibitor (PI or SERPINA1) locus that encodes 1AT have been
described. The common M allele is associated with normal 1AT levels. The S allele, associated with
slightly reduced 1AT levels, and the Z allele, associated with markedly reduced 1AT levels, also
occur with frequencies >1% in most white populations. Rare individuals inherit null alleles, which
lead to the absence of any 1AT production through a heterogeneous collection of mutations.
Individuals with two Z alleles or one Z and one null allele are referred to as PiZ, which is the most
common form of severe 1AT deficiency.
Although only 12% of COPD patients are found to have severe 1AT deficiency as a contributing
cause of COPD, these patients demonstrate that genetic factors can have a profound influence on
the susceptibility for developing COPD. PiZ individuals often develop early-onset COPD, but the
ascertainment bias in the published series of PiZ individualswhich have usually included many PiZ
subjects who were tested for 1AT deficiency because they had COPDmeans that the fraction of
PiZ individuals who will develop COPD and the age-of-onset distribution for the development of
COPD in PiZ subjects remain unknown. Approximately 1 in 3000 individuals in the United States
inherits severe 1AT deficiency, but only a small minority of these individuals has been recognized.
The clinical laboratory test used most frequently to screen for
the immunologic level of

1AT

deficiency is measurement of

AT in serum (see "Laboratory Findings").

A significant percentage of the variability in pulmonary function among PiZ individuals is explained
by cigarette smoking; cigarette smokers with severe 1AT deficiency are more likely to develop
COPD at early ages. However, the development of COPD in PiZ subjects, even among current or exsmokers, is not absolute. Among PiZ nonsmokers, impressive variability has been noted in the
development of airflow obstruction. Asthma and male gender also appear to increase the risk of
COPD in PiZ subjects. Other genetic and/or environmental factors likely contribute to this variability.
Specific treatment in the form of 1AT augmentation therapy is available for severe 1AT deficiency
as a weekly IV infusion (see "Treatment," below).
The risk of lung disease in heterozygous PiMZ individuals, who have intermediate serum levels of
1AT

(~60% of PiMM levels), is controversial. Although previous general population surveys have

not typically shown increased rates of airflow obstruction in PiMZ compared to PiMM individuals,
case-control studies that compared COPD patients to control subjects have usually found an excess
of PiMZ genotypes in the COPD patient group. Several recent large population studies have
suggested that PiMZ subjects are at slightly increased risk for the development of airflow
obstruction, but it remains unclear if all PiMZ subjects are at slightly increased risk for COPD or if a
subset of PiMZ subjects are at substantially increased risk for COPD due to other genetic or
environmental factors.

OTHER GENETIC RISK FACTORS

Studies of pulmonary function measurements performed in general population samples have
suggested that genetic factors other than PI type influence variation in pulmonary function. Familial
aggregation of airflow obstruction within families of COPD patients has also been demonstrated.
Association studies have compared the distribution of variants in candidate genes hypothesized to
be involved in the development of COPD in COPD patients and control subjects. However, the
results have been quite inconsistent, often due to underpowered studies. However, a recent
association study comprising 8300 patients and 7 separate cohorts found that a minor allele SNP of

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 5 of 19

MMP12 (rs2276109) associated with decreased MMP-12 expression has a positive effect on lung
function in children with asthma and in adult smokers. Recent genome-wide association studies
have identified several COPD loci, including a region near the hedgehog interacting protein (HHIP)
gene on chromosome 4 and a cluster of genes on chromosome 15 (including components of the
nicotinic acetylcholine receptor) that likely contain COPD susceptibility determinants, but the specific
genetic determinants in those regions have yet to be definitively identified.

NATURAL HISTORY
The effects of cigarette smoking on pulmonary function appear to depend on the intensity of
smoking exposure, the timing of smoking exposure during growth, and the baseline lung function of
the individual; other environmental factors may have similar effects. Most individuals follow a
steady trajectory of increasing pulmonary function with growth during childhood and adolescence,
followed by a gradual decline with aging. Individuals appear to track in their quartile of pulmonary
function based upon environmental and genetic factors that put them on different tracks. The risk of
eventual mortality from COPD is closely associated with reduced levels of FEV1. A graphic depiction
of the natural history of COPD is shown as a function of the influences on tracking curves of FEV1 in
Fig. 260-2. Death or disability from COPD can result from a normal rate of decline after a reduced
growth phase (curve C), an early initiation of pulmonary function decline after normal growth (curve
B), or an accelerated decline after normal growth (curve D). The rate of decline in pulmonary
function can be modified by changing environmental exposures (i.e., quitting smoking), with
smoking cessation at an earlier age providing a more beneficial effect than smoking cessation after
marked reductions in pulmonary function have already developed. Genetic factors likely contribute
to the level of pulmonary function achieved during growth and to the rate of decline in response to
smoking and potentially to other environmental factors as well.

Figure 260-2

Hypothetical tracking curves of FEV1for individuals throughout their life spans. The normal pattern
of growth and decline with age is shown by curve A. Significantly reduced FEV1 (<65% of predicted value at
age 20) can develop from a normal rate of decline after a reduced pulmonary function growth phase (curve
C), early initiation of pulmonary function decline after normal growth (curve B), or accelerated decline after

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 6 of 19

normal growth (curve D). (From B Rijcken: Doctoral dissertation, p 133, University of Groningen, 1991;
with permission.)

PATHOPHYSIOLOGY
Persistent reduction in forced expiratory flow rates is the most typical finding in COPD. Increases in
the residual volume and the residual volume/total lung capacity ratio, nonuniform distribution of
ventilation, and ventilation-perfusion mismatching also occur.

Airflow Obstruction
Airflow limitation, also known as airflow obstruction, is typically determined by spirometry, which
involves forced expiratory maneuvers after the subject has inhaled to total lung capacity. Key
parameters obtained from spirometry include FEV1 and the total volume of air exhaled during the
entire spirometric maneuver [forced vital capacity (FVC)]. Patients with airflow obstruction related
to COPD have a chronically reduced ratio of FEV1/FVC. In contrast to asthma, the reduced FEV1 in
COPD seldom shows large responses to inhaled bronchodilators, although improvements up to 15%
are common. Asthma patients can also develop chronic (not fully reversible) airflow obstruction.
Airflow during forced exhalation is the result of the balance between the elastic recoil of the lungs
promoting flow and the resistance of the airways limiting flow. In normal lungs, as well as in lungs
affected by COPD, maximal expiratory flow diminishes as the lungs empty because the lung
parenchyma provides progressively less elastic recoil and because the cross-sectional area of the
airways falls, raising the resistance to airflow. The decrease in flow coincident with decreased lung
volume is readily apparent on the expiratory limb of a flow-volume curve. In the early stages of
COPD, the abnormality in airflow is only evident at lung volumes at or below the functional residual
capacity (closer to residual volume), appearing as a scooped-out lower part of the descending limb
of the flow-volume curve. In more advanced disease the entire curve has decreased expiratory flow
compared to normal.

Hyperinflation
Lung volumes are also routinely assessed in pulmonary function testing. In COPD there is often "air
trapping" (increased residual volume and increased ratio of residual volume to total lung capacity)
and progressive hyperinflation (increased total lung capacity) late in the disease. Hyperinflation of
the thorax during tidal breathing preserves maximum expiratory airflow, because as lung volume
increases, elastic recoil pressure increases, and airways enlarge so that airway resistance
decreases.
Despite compensating for airway obstruction, hyperinflation can push the diaphragm into a flattened
position with a number of adverse effects. First, by decreasing the zone of apposition between the
diaphragm and the abdominal wall, positive abdominal pressure during inspiration is not applied as
effectively to the chest wall, hindering rib cage movement and impairing inspiration. Second,
because the muscle fibers of the flattened diaphragm are shorter than those of a more normally
curved diaphragm, they are less capable of generating inspiratory pressures than normal. Third, the
flattened diaphragm (with increased radius of curvature, r) must generate greater tension (t) to
develop the transpulmonary pressure (p) required to produce tidal breathing. This follows from
Laplace's law, p = 2t/r. Also, because the thoracic cage is distended beyond its normal resting
volume, during tidal breathing the inspiratory muscles must do work to overcome the resistance of
the thoracic cage to further inflation instead of gaining the normal assistance from the chest wall
recoiling outward toward its resting volume.

Gas Exchange
Although there is considerable variability in the relationships between the FEV1 and other

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 7 of 19

physiologic abnormalities in COPD, certain generalizations may be made. The PaO usually remains
2

near normal until the FEV1 is decreased to ~50% of predicted, and even much lower FEV1 values
can be associated with a normal PaO , at least at rest. An elevation of arterial level of carbon
2

dioxide (PaCO ) is not expected until the FEV1 is <25% of predicted and even then may not occur.
2
Pulmonary hypertension severe enough to cause cor pulmonale and right ventricular failure due to
COPD typically occurs in individuals who have marked decreases in FEV1 (<25% of predicted) and
chronic hypoxemia (PaO <55 mmHg); however, recent evidence suggests that some patients will
2

develop significant pulmonary hypertension independent of COPD severity (Chap. 250).

Nonuniform ventilation and ventilation-perfusion mismatching are characteristic of COPD, reflecting
the heterogeneous nature of the disease process within the airways and lung parenchyma.
Physiologic studies are consistent with multiple parenchymal compartments having different rates of
ventilation due to regional differences in compliance and airway resistance. Ventilation-perfusion
mismatching accounts for essentially all of the reduction in PaO that occurs in COPD; shunting is
2

minimal. This finding explains the effectiveness of modest elevations of inspired oxygen in treating
hypoxemia due to COPD and therefore the need to consider problems other than COPD when
hypoxemia is difficult to correct with modest levels of supplemental oxygen in the patient with
COPD.

PATHOLOGY
Cigarette smoke exposure may affect the large airways, small airways ( 2 mm diameter), and
alveoli. Changes in large airways cause cough and sputum, while changes in small airways and
alveoli are responsible for physiologic alterations. Emphysema and small airway pathology are both
present in most persons with COPD; however, they do not appear to be mechanistically related to
each other, and their relative contributions to obstruction vary from one person to another.

Large Airway
Cigarette smoking often results in mucous gland enlargement and goblet cell hyperplasia leading to
cough and mucus production that define chronic bronchitis, but these abnormalities are not related
to airflow limitation. Goblet cells not only increase in number but in extent through the bronchial
tree. Bronchi also undergo squamous metaplasia, predisposing to carcinogenesis and disrupting
mucociliary clearance. Although not as prominent as in asthma, patients may have smooth-muscle
hypertrophy and bronchial hyperreactivity leading to airflow limitation. Neutrophil influx has been
associated with purulent sputum of upper respiratory tract infections. Independent of its proteolytic
activity, neutrophil elastase is among the most potent secretagogues identified.

Small Airways
The major site of increased resistance in most individuals with COPD is in airways 2 mm diameter.
Characteristic cellular changes include goblet cell metaplasia, with these mucus-secreting cells
replacing surfactant-secreting Clara cells. Infiltration of mononuclear phagocytes is also prominent.
Smooth-muscle hypertrophy may also be present. These abnormalities may cause luminal
narrowing by fibrosis, excess mucus, edema, and cellular infiltration. Reduced surfactant may
increase surface tension at the air-tissue interface, predisposing to airway narrowing or collapse.
Respiratory bronchiolitis with mononuclear inflammatory cells collecting in distal airway tissues may
cause proteolytic destruction of elastic fibers in the respiratory bronchioles and alveolar ducts where
the fibers are concentrated as rings around alveolar entrances.
Because small airway patency is maintained by the surrounding lung parenchyma that provides
radial traction on bronchioles at points of attachment to alveolar septa, loss of bronchiolar
attachments as a result of extracellular matrix destruction may cause airway distortion and
narrowing in COPD.

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 8 of 19

Lung Parenchyma
Emphysema is characterized by destruction of gas-exchanging air spaces, i.e., the respiratory
bronchioles, alveolar ducts, and alveoli. Their walls become perforated and later obliterated with
coalescence of small distinct air spaces into abnormal and much larger air spaces. Macrophages
accumulate in respiratory bronchioles of essentially all young smokers. Bronchoalveolar lavage fluid
from such individuals contains roughly five times as many macrophages as lavage from
nonsmokers. In smokers' lavage fluid, macrophages comprise >95% of the total cell count, and
neutrophils, nearly absent in nonsmokers' lavage, account for 12% of the cells. T lymphocytes,
particularly CD8+ cells, are also increased in the alveolar space of smokers.
Emphysema is classified into distinct pathologic types, the most important being centriacinar and
panacinar. Centriacinar emphysema, the type most frequently associated with cigarette smoking, is
characterized by enlarged air spaces found (initially) in association with respiratory bronchioles.
Centriacinar emphysema is usually most prominent in the upper lobes and superior segments of
lower lobes and is often quite focal. Panacinar emphysema refers to abnormally large air spaces
evenly distributed within and across acinar units. Panacinar emphysema is usually observed in
patients with 1AT deficiency, which has a predilection for the lower lobes. Distinctions between
centriacinar and panacinar emphysema are interesting and may ultimately be shown to have
different mechanisms of pathogenesis. However, garden-variety smoking-related emphysema is
usually mixed, particularly in advanced cases, and these pathologic classifications are not helpful in
the care of patients with COPD.

PATHOGENESIS
Airflow limitation, the major physiologic change in COPD, can result from both small airway
obstruction and emphysema, as discussed above. Pathologic findings that can contribute to small
airway obstruction are described above, but their relative importance is unknown. Fibrosis
surrounding the small airways appears to be a significant contributor. Mechanisms leading to
collagen accumulation around the airways in the face of increased collagenase activity remain an
enigma. Although seemingly counterintuitive, there are several potential mechanisms whereby a
proteinase can predispose to fibrosis, including proteolytic activation of transforming growth factor
(TGF- ). Largely due to greater similarity of animal air spaces than airways to humans, we know
much more about mechanisms involved in emphysema than small airway obstruction.
The dominant paradigm of the pathogenesis of emphysema comprises four interrelated events (Fig.
260-3): (1) Chronic exposure to cigarette smoke may lead to inflammatory cell recruitment within
the terminal air spaces of the lung. (2) These inflammatory cells release elastolytic proteinases that
damage the extracellular matrix of the lung. (3) Structural cell death results from oxidant stress and
loss of matrix-cell attachment. (4) Ineffective repair of elastin and other extracellular matrix
components result in air space enlargement that defines pulmonary emphysema.

Figure 260-3

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 9 of 19

Pathogenesis of emphysema. Upon long-term exposure to cigarette smoke, inflammatory cells are
recruited to the lung; they release proteinases in excess of inhibitors, and if repair is abnormal, this leads
to air space destruction and enlargement or emphysema. ECM, extracellular matrix; MMP, matrix
metalloproteinase.

The Elastase:Antielastase Hypothesis

Elastin, the principal component of elastic fibers, is a highly stable component of the extracellular
matrix that is critical to the integrity of the lung. The elastase:antielastase hypothesis proposed in
the mid-1960s states that the balance of elastin-degrading enzymes and their inhibitors determines
the susceptibility of the lung to destruction resulting in air space enlargement. This hypothesis was
based on the clinical observation that patients with genetic deficiency in 1AT, the inhibitor of the
serine proteinase neutrophil elastase, were at increased risk of emphysema, and that instillation of
elastases, including neutrophil elastase, to experimental animals results in emphysema. The
elastase:antielastase hypothesis remains a prevailing mechanism for the development of
emphysema. However, a complex network of immune and inflammatory cells and additional
proteinases that contribute to emphysema have subsequently been identified.

INFLAMMATION AND EXTRACELLULAR MATRIX PROTEOLYSIS

Macrophages patrol the lower air space under normal conditions. Upon exposure to oxidants from

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 10 of 19

cigarette smoke, macrophages become activated, producing proteinases and chemokines that
attract other inflammatory cells. One mechanism of macrophage activation occurs via oxidantinduced inactivation of histone deacetylase-2, shifting the balance toward acetylated or loose
chromatin, exposing nuclear factor B sites and resulting in transcription of matrix
metalloproteinases, proinflammatory cytokines such as interleukin 8 (IL-8), and tumor necrosis
factor (TNF- ); this leads to neutrophil recruitment. CD8+ T cells are also recruited in response to
cigarette smoke and release interferon inducible protein-10 (IP-10, CXCL-7) that in turn leads to
macrophage production of macrophage elastase [matrix metalloproteinase-12 (MMP-12)]. Matrix
metalloproteinases and serine proteinases, most notably neutrophil elastase, work together by
degrading the inhibitor of the other, leading to lung destruction. Proteolytic cleavage products of
elastin also serve as a macrophage chemokine, fueling this destructive positive feedback loop.
Autoimmune mechanisms have recently been identified in COPD and may promote the progression
of disease. Increased B cells and lymphoid follicles are present in patients, particularly those with
advanced disease. Antibodies have been found against elastin fragments, as well; IgG
autoantibodies with avidity for pulmonary epithelium and the potential to mediate cytotoxicity have
been detected.
Concomitant cigarette smokeinduced loss of cilia in the airway epithelium and impaired
macrophage phagocytosis predispose to bacterial infection with neutrophilia. In end-stage lung
disease, long after smoking cessation there remains an exuberant inflammatory response,
suggesting that mechanisms of cigarette smokeinduced inflammation that initiate the disease differ
from mechanisms that sustain inflammation after smoking cessation.

CELL DEATH
Air space enlargement with loss of alveolar units obviously requires disappearance of both
extracellular matrix and cells. Cell death can occur from increased oxidant stress both directly from
cigarette smoke and from inflammation. Animal models have used endothelial and epithelial cell
death as a means to generate transient air space enlargement. Uptake of apoptotic cells by
macrophages results in production of growth factors and dampens inflammation, promoting lung
repair. Cigarette smoke impairs macrophage uptake of apoptotic cells, limiting repair.

INEFFECTIVE REPAIR
The ability of the adult lung to repair damaged alveoli appears limited. It is unlikely that the process
of septation that is responsible for alveologenesis during lung development can be reinitiated. The
capacity of stem cells to repopulate the lung is under active investigation. It appears difficult for an
adult human to completely restore an appropriate extracellular matrix, particularly functional elastic
fibers.

CLINICAL PRESENTATION
History
The three most common symptoms in COPD are cough, sputum production, and exertional dyspnea.
Many patients have such symptoms for months or years before seeking medical attention. Although
the development of airflow obstruction is a gradual process, many patients date the onset of their
disease to an acute illness or exacerbation. A careful history, however, usually reveals the presence
of symptoms prior to the acute exacerbation. The development of exertional dyspnea, often
described as increased effort to breathe, heaviness, air hunger, or gasping, can be insidious. It is
best elicited by a careful history focused on typical physical activities and how the patient's ability to
perform them has changed. Activities involving significant arm work, particularly at or above
shoulder level, are particularly difficult for patients with COPD. Conversely, activities that allow the
patient to brace the arms and use accessory muscles of respiration are better tolerated. Examples
of such activities include pushing a shopping cart, walking on a treadmill, or pushing a wheelchair.

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 11 of 19

As COPD advances, the principal feature is worsening dyspnea on exertion with increasing intrusion
on the ability to perform vocational or avocational activities. In the most advanced stages, patients
are breathless doing simple activities of daily living.
Accompanying worsening airflow obstruction is an increased frequency of exacerbations (described
below). Patients may also develop resting hypoxemia and require institution of supplemental
oxygen.

Physical Findings
In the early stages of COPD, patients usually have an entirely normal physical examination. Current
smokers may have signs of active smoking, including an odor of smoke or nicotine staining of
fingernails. In patients with more severe disease, the physical examination is notable for a
prolonged expiratory phase and may include expiratory wheezing. In addition, signs of
hyperinflation include a barrel chest and enlarged lung volumes with poor diaphragmatic excursion
as assessed by percussion. Patients with severe airflow obstruction may also exhibit use of
accessory muscles of respiration, sitting in the characteristic "tripod" position to facilitate the actions
of the sternocleidomastoid, scalene, and intercostal muscles. Patients may develop cyanosis, visible
in the lips and nail beds.
Although traditional teaching is that patients with predominant emphysema, termed "pink puffers,"
are thin and noncyanotic at rest and have prominent use of accessory muscles, and patients with
chronic bronchitis are more likely to be heavy and cyanotic ("blue bloaters"), current evidence
demonstrates that most patients have elements of both bronchitis and emphysema and that the
physical examination does not reliably differentiate the two entities.
Advanced disease may be accompanied by systemic wasting, with significant weight loss,
bitemporal wasting, and diffuse loss of subcutaneous adipose tissue. This syndrome has been
associated with both inadequate oral intake and elevated levels of inflammatory cytokines (TNF- ).
Such wasting is an independent poor prognostic factor in COPD. Some patients with advanced
disease have paradoxical inward movement of the rib cage with inspiration (Hoover's sign), the
result of alteration of the vector of diaphragmatic contraction on the rib cage as a result of chronic
hyperinflation.
Signs of overt right heart failure, termed cor pulmonale, are relatively infrequent since the advent of
supplemental oxygen therapy.
Clubbing of the digits is not a sign of COPD, and its presence should alert the clinician to initiate an
investigation for causes of clubbing. In this population, the development of lung cancer is the most
likely explanation for newly developed clubbing.

Laboratory Findings
The hallmark of COPD is airflow obstruction (discussed above). Pulmonary function testing shows
airflow obstruction with a reduction in FEV1 and FEV1/FVC (Chap. 252). With worsening disease
severity, lung volumes may increase, resulting in an increase in total lung capacity, functional
residual capacity, and residual volume. In patients with emphysema, the diffusing capacity may be
reduced, reflecting the lung parenchymal destruction characteristic of the disease. The degree of
airflow obstruction is an important prognostic factor in COPD and is the basis for the Global
Initiative for Lung Disease (GOLD) redundant classification (Table 260-1). More recently it has
been shown that a multifactorial index incorporating airflow obstruction, exercise performance,
dyspnea, and body mass index is a better predictor of mortality rate than pulmonary function alone.

Table 260-1 Gold Criteria for COPD Severity

GOLD

Severity

Symptoms

Spirometry

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 12 of 19

Stage
0

At Risk

Chronic cough, sputum

production

Normal

Mild

With or without chronic cough

or sputum production

FEV1/FVC <0.7 and FEV1

IIA

Moderate

With or without chronic cough

or sputum production

FEV1/FVC <0.7 and 50% FEV1 <80%

With or without chronic cough

or sputum production

FEV1/FVC <0.7 and 30% FEV1 <50%

With or without chronic cough

or sputum production

FEV1/FVC <0.7 and FEV1 <30% predicted

III

IV

Severe

Very
Severe

80% predicted

predicted

predicted

or
FEV1 <50% predicted with respiratory
failure or signs of right heart failure

Abbreviation: GOLD, Global Initiative for Lung Disease.

Source: From RA Pauwels et al.
Arterial blood gases and oximetry may demonstrate resting or exertional hypoxemia. Arterial blood
gases provide additional information about alveolar ventilation and acid-base status by measuring
arterial PCO and pH. The change in pH with PCO is 0.08 units/10 mmHg acutely and 0.03 units/10
2

mmHg in the chronic state. Knowledge of the arterial pH therefore allows the classification of
ventilatory failure, defined as PCO >45 mmHg, into acute or chronic conditions. The arterial blood
2

gas is an important component of the evaluation of patients presenting with symptoms of an

exacerbation. An elevated hematocrit suggests the presence of chronic hypoxemia, as does the
presence of signs of right ventricular hypertrophy.
Radiographic studies may assist in the classification of the type of COPD. Obvious bullae, paucity of
parenchymal markings, or hyperlucency suggests the presence of emphysema. Increased lung
volumes and flattening of the diaphragm suggest hyperinflation but do not provide information
about chronicity of the changes. Computed tomography (CT) scan is the current definitive test for
establishing the presence or absence of emphysema in living subjects (Fig. 260-4). From a
practical perspective, the CT scan does little to influence therapy of COPD except in those
individuals considering surgical therapy for their disease (described below).

Figure 260-4

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 13 of 19

Chest CT scan of a patient with COPD who underwent a left single-lung transplant. Note the
reduced parenchymal markings in the right lung (left side of figure) as compared to the left lung,
representing emphysematous destruction of the lung, and mediastinal shift to the left, indicative of
hyperinflation.

Recent guidelines have suggested testing for 1AT deficiency in all subjects with COPD or asthma
with chronic airflow obstruction. Measurement of the serum 1AT level is a reasonable initial test.
For subjects with low 1AT levels, the definitive diagnosis of 1AT deficiency requires protease
inhibitor (PI) type determination. This is typically performed by isoelectric focusing of serum, which
reflects the genotype at the PI locus for the common alleles and many of the rare PI alleles as well.
Molecular genotyping of DNA can be performed for the common PI alleles (M, S, and Z).

Treatment: Chronic Obstructive Pulmonary Disease

STABLE PHASE COPD
Only three interventionssmoking cessation, oxygen therapy in chronically hypoxemic patients, and
lung volume reduction surgery in selected patients with emphysemahave been demonstrated to
influence the natural history of patients with COPD. There is currently suggestive, but not definitive,
evidence that the use of inhaled glucocorticoids may alter mortality rate (but not lung function). All
other current therapies are directed at improving symptoms and decreasing the frequency and
severity of exacerbations. The institution of these therapies should involve an assessment of
symptoms, potential risks, costs, and benefits of therapy. This should be followed by an assessment
of response to therapy, and a decision should be made whether or not to continue treatment.

PHARMACOTHERAPY

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 14 of 19

Smoking Cessation (See Also Chap. 395)

It has been shown that middle-aged smokers who were able to successfully stop smoking
experienced a significant improvement in the rate of decline in pulmonary function, returning to
annual changes similar to that of nonsmoking patients. Thus, all patients with COPD should be
strongly urged to quit and educated about the benefits of quitting. An emerging body of evidence
demonstrates that combining pharmacotherapy with traditional supportive approaches considerably
enhances the chances of successful smoking cessation. There are three principal pharmacologic
approaches to the problem: bupropion, originally developed as an antidepressant medication;
nicotine replacement therapy available as gum, transdermal patch, inhaler, and nasal spray; and
varenicline, a nicotinic acid receptor agonist/antagonist. Current recommendations from the U.S.
Surgeon General are that all adult, nonpregnant smokers considering quitting be offered
pharmacotherapy, in the absence of any contraindication to treatment.

Bronchodilators
In general, bronchodilators are used for symptomatic benefit in patients with COPD. The inhaled
route is preferred for medication delivery as the incidence of side effects is lower than that seen
with the use of parenteral medication delivery.

Anticholinergic Agents
Ipratropium bromide improves symptoms and produces acute improvement in FEV1. Tiotropium, a
long-acting anticholinergic, has been shown to improve symptoms and reduce exacerbations.
Studies of both ipratropium and tiotropium have failed to demonstrate that either influences the
rate of decline in FEV1. In a large randomized clinical trial, there was a trend toward reduced
mortality rate in the tiotropium-treated patients that approached, but did not reach, statistical
significance. Side effects are minor, and a trial of inhaled anticholinergics is recommended in
symptomatic patients with COPD.

Beta Agonists
These provide symptomatic benefit. The main side effects are tremor and tachycardia. Long-acting
inhaled agonists, such as salmeterol, have benefits comparable to ipratropium bromide. Their use
is more convenient than short-acting agents. The addition of a agonist to inhaled anticholinergic
therapy has been demonstrated to provide incremental benefit. A recent report in asthma suggests
that those patients, particularly African Americans, using a long-acting agonist without
concomitant inhaled corticosteroids have an increased risk of deaths from respiratory causes. The
applicability of these data to patients with COPD is unclear.

Inhaled Glucocorticoids
Although a recent trial demonstrated an apparent benefit from the regular use of inhaled
glucocorticoids on the rate of decline of lung function, a number of other well-designed randomized
trials have not. Patients studied included those with mild to severe airflow obstruction and current
and ex-smokers. Patients with significant acute response to inhaled agonists were excluded from
many of these trials, which may impact the generalizability of the findings. Their use has been
associated with increased rates of oropharyngeal candidiasis and an increased rate of loss of bone
density. Available data suggest that inhaled glucocorticoids reduce exacerbation frequency by
~25%. The impact of inhaled corticosteroids on mortality rates in COPD is controversial. A metaanalysis and several retrospective studies suggest a mortality benefit, but in a recently published
randomized trial, differences in mortality rate approached, but did not reach, conventional criteria
for statistical significance. A trial of inhaled glucocorticoids should be considered in patients with
frequent exacerbations, defined as two or more per year, and in patients who demonstrate a
significant amount of acute reversibility in response to inhaled bronchodilators.

Oral Glucocorticoids

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 15 of 19

The chronic use of oral glucocorticoids for treatment of COPD is not recommended because of an
unfavorable benefit/risk ratio. The chronic use of oral glucocorticoids is associated with significant
side effects, including osteoporosis, weight gain, cataracts, glucose intolerance, and increased risk
of infection. A recent study demonstrated that patients tapered off chronic low-dose prednisone
(~10 mg/d) did not experience any adverse effect on the frequency of exacerbations, health-related
quality of life, or lung function. On average, patients lost ~4.5 kg (~10 lb) when steroids were
withdrawn.

Theophylline
Theophylline produces modest improvements in expiratory flow rates and vital capacity and a slight
improvement in arterial oxygen and carbon dioxide levels in patients with moderate to severe
COPD. Nausea is a common side effect; tachycardia and tremor have also been reported. Monitoring
of blood theophylline levels is typically required to minimize toxicity.

Oxygen
Supplemental O2 is the only pharmacologic therapy demonstrated to unequivocally decrease
mortality rates in patients with COPD. For patients with resting hypoxemia (resting O2 saturation
88% or <90% with signs of pulmonary hypertension or right heart failure), the use of O2 has been
demonstrated to have a significant impact on mortality rate. Patients meeting these criteria should
be on continual oxygen supplementation, as the mortality benefit is proportional to the number of
hours/day oxygen is used. Various delivery systems are available, including portable systems that
patients may carry to allow mobility outside the home.
Supplemental O2 is commonly prescribed for patients with exertional hypoxemia or nocturnal
hypoxemia. Although the rationale for supplemental O2 in these settings is physiologically sound,
the benefits of such therapy are not well substantiated.

Other Agents
N-acetyl cysteine has been used in patients with COPD for both its mucolytic and antioxidant
properties. A prospective trial failed to find any benefit with respect to decline in lung function or
prevention of exacerbations. Specific treatment in the form of IV 1AT augmentation therapy is
available for individuals with severe

AT deficiency. Despite sterilization procedures for these

blood-derived products and the absence of reported cases of viral infection from therapy, some
physicians recommend hepatitis B vaccination prior to starting augmentation therapy. Although
biochemical efficacy of 1AT augmentation therapy has been shown, a randomized controlled trial of
1

AT augmentation therapy has not definitively established the efficacy of augmentation therapy in

reducing decline of pulmonary function. Eligibility for 1AT augmentation therapy requires a serum
AT level <11 M (approximately 50 mg/dL). Typically, PiZ individuals will qualify, although other
1
rare types associated with severe deficiency (e.g., null-null) are also eligible. Since only a fraction of
individuals with severe 1AT deficiency will develop COPD, 1AT augmentation therapy is not
recommended for severely 1AT-deficient persons with normal pulmonary function and a normal
chest CT scan.

NONPHARMACOLOGIC THERAPIES
General Medical Care
Patients with COPD should receive the influenza vaccine annually. Polyvalent pneumococcal vaccine
is also recommended, although proof of efficacy in this patient population is not definitive.

Pulmonary Rehabilitation
This refers to a treatment program that incorporates education and cardiovascular conditioning. In
COPD, pulmonary rehabilitation has been demonstrated to improve health-related quality of life,

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 16 of 19

dyspnea, and exercise capacity. It has also been shown to reduce rates of hospitalization over a 6to 12-month period.

Lung Volume Reduction Surgery (LVRS)

Surgery to reduce the volume of lung in patients with emphysema was first introduced with minimal
success in the 1950s and was reintroduced in the 1990s. Patients are excluded if they have
significant pleural disease, a pulmonary artery systolic pressure >45 mmHg, extreme
deconditioning, congestive heart failure, or other severe comorbid conditions. Patients with an FEV1
<20% of predicted and either diffusely distributed emphysema on CT scan or diffusing capacity of
lung for carbon monoxide (DLCO) <20% of predicted have an increased mortality rate after the
procedure and thus are not candidates for LVRS.
The National Emphysema Treatment trial demonstrated that LVRS offers both a mortality benefit
and a symptomatic benefit in certain patients with emphysema. The anatomic distribution of
emphysema and postrehabilitation exercise capacity are important prognostic characteristics.
Patients with upper lobepredominant emphysema and a low postrehabilitation exercise capacity
are most likely to benefit from LVRS.

Lung Transplantation (See Also Chap. 266)

COPD is currently the second leading indication for lung transplantation (Fig. 260-4). Current
recommendations are that candidates for lung transplantation should be <65 years; have severe
disability despite maximal medical therapy; and be free of comorbid conditions such as liver, renal,
or cardiac disease. In contrast to LVRS, the anatomic distribution of emphysema and the presence
of pulmonary hypertension are not contraindications to lung transplantation. Unresolved issues
concerning lung transplantation and COPD include whether single- or double-lung transplant is the
preferred procedure.

EXACERBATIONS OF COPD
Exacerbations are a prominent feature of the natural history of COPD. Exacerbations are episodes of
increased dyspnea and cough and change in the amount and character of sputum. They may or may
not be accompanied by other signs of illness, including fever, myalgias, and sore throat. Selfreported health-related quality of life correlates with frequency of exacerbations more closely than it
does with the degree of airflow obstruction. Economic analyses have shown that >70% of COPDrelated health care expenditures go to emergency department visits and hospital care; this
translates to >$10 billion annually in the United States. The frequency of exacerbations increases as
airflow obstruction increases; patients with moderate to severe airflow obstruction [GOLD stages
III, IV (Table 260-1)] on average have one to three episodes per year. However, some individuals
with very severe airflow obstruction do not have frequent exacerbations; the history of prior
exacerbations is a strong predictor of future exacerbations.
The approach to the patient experiencing an exacerbation includes an assessment of the severity of
the patient's illness, both acute and chronic components; an attempt to identify the precipitant of
the exacerbation; and the institution of therapy.

Precipitating Causes and Strategies to Reduce Frequency of

Exacerbations
A variety of stimuli may result in the final common pathway of airway inflammation and increased
symptoms that are characteristic of COPD exacerbations. Bacterial infections play a role in many,
but by no means all, episodes. Viral respiratory infections are present in approximately one-third of
COPD exacerbations. In a significant minority of instances (2035%), no specific precipitant can be
identified.
Despite the frequent implication of bacterial infection, chronic suppressive or "rotating" antibiotics

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 17 of 19

are not beneficial in patients with COPD. This is in contrast to their efficacy in patients with
bronchiectasis due to cystic fibrosis, in whom suppressive antibiotics have been shown to reduce
frequency of hospital admissions.
The role of pharmacotherapy in reducing exacerbation frequency is less well studied. Chronic oral
glucocorticoids are not recommended for this purpose. Inhaled glucocorticoids reduce the frequency
of exacerbations by 2530% in most analyses. The use of inhaled glucocorticoids should be
considered in patients with frequent exacerbations or those who have an asthmatic component, i.e.,
significant reversibility on pulmonary function testing or marked symptomatic improvement after
inhaled bronchodilators. Similar magnitudes of reduction have been reported for anticholinergic and
long-acting beta-agonist therapy. The influenza vaccine has been shown to reduce exacerbation
rates in patients with COPD.

Patient Assessment
An attempt should be made to establish the severity of the exacerbation as well as the severity of
preexisting COPD. The more severe either of these two components, the more likely that the patient
will require hospital admission. The history should include quantification of the degree of dyspnea by
asking about breathlessness during activities of daily living and typical activities for the patient. The
patient should be asked about fever; change in character of sputum; any ill contacts; and
associated symptoms such as nausea, vomiting, diarrhea, myalgias, and chills. Inquiring about the
frequency and severity of prior exacerbations can provide important information.
The physical examination should incorporate an assessment of the degree of distress of the patient.
Specific attention should be focused on tachycardia, tachypnea, use of accessory muscles, signs of
perioral or peripheral cyanosis, the ability to speak in complete sentences, and the patient's mental
status. The chest examination should establish the presence or absence of focal findings, degree of
air movement, presence or absence of wheezing, asymmetry in the chest examination (suggesting
large airway obstruction or pneumothorax mimicking an exacerbation), and the presence or absence
of paradoxical motion of the abdominal wall.
Patients with severe underlying COPD, who are in moderate or severe distress or those with focal
findings should have a chest x-ray. Approximately 25% of x-rays in this clinical situation will be
abnormal, with the most frequent findings being pneumonia and congestive heart failure. Patients
with advanced COPD, those with a history of hypercarbia, those with mental status changes
(confusion, sleepiness), or those in significant distress should have an arterial blood-gas
measurement. The presence of hypercarbia, defined as a PCO >45 mmHg, has important
2

implications for treatment (discussed below). In contrast to its utility in the management of
exacerbations of asthma, measurement of pulmonary function has not been demonstrated to be
helpful in the diagnosis or management of exacerbations of COPD.
There are no definitive guidelines concerning the need for inpatient treatment of exacerbations.
Patients with respiratory acidosis and hypercarbia, significant hypoxemia, or severe underlying
disease or those whose living situation is not conducive to careful observation and the delivery of
prescribed treatment should be admitted to the hospital.

ACUTE EXACERBATIONS
Bronchodilators
Typically, patients are treated with an inhaled agonist, often with the addition of an anticholinergic
agent. These may be administered separately or together, and the frequency of administration
depends on the severity of the exacerbation. Patients are often treated initially with nebulized
therapy, as such treatment is often easier to administer in older patients or to those in respiratory
distress. It has been shown, however, that conversion to metered-dose inhalers is effective when

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 18 of 19

accompanied by education and training of patients and staff. This approach has significant economic
benefits and also allows an easier transition to outpatient care. The addition of methylxanthines
(such as theophylline) to this regimen can be considered, although convincing proof of its efficacy is
lacking. If added, serum levels should be monitored in an attempt to minimize toxicity.

Antibiotics
Patients with COPD are frequently colonized with potential respiratory pathogens, and it is often
difficult to identify conclusively a specific species of bacteria responsible for a particular clinical
event. Bacteria frequently implicated in COPD exacerbations include Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella catarrhalis. In addition, Mycoplasma pneumoniae or
Chlamydia pneumoniae are found in 510% of exacerbations. The choice of antibiotic should be
based on local patterns of antibiotic susceptibility of the above pathogens as well as the patient's
clinical condition. Most practitioners treat patients with moderate or severe exacerbations with
antibiotics, even in the absence of data implicating a specific pathogen.

Glucocorticoids
Among patients admitted to the hospital, the use of glucocorticoids has been demonstrated to
reduce the length of stay, hasten recovery, and reduce the chance of subsequent exacerbation or
relapse for a period of up to 6 months. One study demonstrated that 2 weeks of glucocorticoid
therapy produced benefit indistinguishable from 8 weeks of therapy. The GOLD guidelines
recommend 3040 mg of oral prednisolone or its equivalent for a period of 1014 days.
Hyperglycemia, particularly in patients with preexisting diagnosis of diabetes, is the most frequently
reported acute complication of glucocorticoid treatment.

Oxygen
Supplemental O2 should be supplied to keep arterial saturations 90%. Hypoxemic respiratory drive
plays a small role in patients with COPD. Studies have demonstrated that in patients with both
acute and chronic hypercarbia, the administration of supplemental O2 does not reduce minute
ventilation. It does, in some patients, result in modest increases in arterial PCO , chiefly by altering
2
ventilation-perfusion relationships within the lung. This should not deter practitioners from providing
the oxygen needed to correct hypoxemia.

Mechanical Ventilatory Support

The initiation of noninvasive positive-pressure ventilation (NIPPV) in patients with respiratory
failure, defined as PaCO >45 mmHg, results in a significant reduction in mortality rate, need for
2

intubation, complications of therapy, and hospital length of stay. Contraindications to NIPPV include
cardiovascular instability, impaired mental status or inability to cooperate, copious secretions or the
inability to clear secretions, craniofacial abnormalities or trauma precluding effective fitting of mask,
extreme obesity, or significant burns.
Invasive (conventional) mechanical ventilation via an endotracheal tube is indicated for patients
with severe respiratory distress despite initial therapy, life-threatening hypoxemia, severe
hypercarbia and/or acidosis, markedly impaired mental status, respiratory arrest, hemodynamic
instability, or other complications. The goal of mechanical ventilation is to correct the
aforementioned conditions. Factors to consider during mechanical ventilatory support include the
need to provide sufficient expiratory time in patients with severe airflow obstruction and the
presence of auto-PEEP (positive end-expiratory pressure), which can result in patients having to
generate significant respiratory effort to trigger a breath during a demand mode of ventilation. The
mortality rate of patients requiring mechanical ventilatory support is 1730% for that particular
hospitalization. For patients age >65 admitted to the intensive care unit for treatment, the mortality
rate doubles over the next year to 60%, regardless of whether mechanical ventilation was required.

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016

AccessMedicine | Print: Chapter 260. Chronic Obstructive Pulmonary Disease

Page 19 of 19

FURTHER READINGS
American Thoracic Society/European Respiratory Society Task Force: Standards for the diagnosis
and management of patients with COPD [Internet]. Version 1.2. New York: American Thoracic
Society; 2004 [updated September 8, 2005]. Available from http://www-test.thoracic.org/copd/
Fiore MC et al: Treating Tobacco Use and Dependence, Clinical Practice Guideline. Rockville, MD:
U.S. Department of Health and Human Services. Public Health Service, June 2000
Hunninghake GM et al: MMP12, lung function, and COPD in high-risk populations. N Engl J Med
361:2599, 2009[PMID: 20018959] [Full Text]
Ito K et al: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl
J Med 352:1967, 2005[PMID: 15888697] [Full Text]
Mannino DM, Buist AS: Global burden of COPD: Risk factors, prevalence, and future trends. Lancet
370:765, 2007[PMID: 17765526] [Full Text]
Rabe KF et al: Global strategy for the diagnosis, management and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532, 2007[PMID:
17507545] [Full Text]
et al: Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med
175:1222, 2007
Sin DD et al: Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax
60:992, 2005[PMID: 16227327] [Full Text]
Wise RA, Tashkin DP: Optimizing treatment of chronic obstructive pulmonary disease: An
assessment of current therapies. Am J Med 120:S4, 2007

Copyright The McGraw-Hill Companies. All rights reserved.

mk:@MSITStore:C:\New%20folder\KULIAH\Medical%20E-Books\Internal%20Me...

26/10/2016